QPPV.COM

Inspection Interviews in Pharmacovigilance

A practical guide to pharmacovigilance inspection interviews, interview preparation, inspector expectations and common interview mistakes.

Audio Lesson 11 min

Inspection Interviews in Pharmacovigilance

Introduction

For many pharmacovigilance professionals, inspection interviews are among the most stressful parts of a regulatory inspection.

Documents can be reviewed in advance.

Metrics can be prepared.

Reports can be organised.

Interviews are different.

They require individuals to demonstrate:

in real time.

Importantly, inspectors are rarely assessing memory.

They are assessing whether individuals understand their responsibilities and can demonstrate effective control of the pharmacovigilance system.

A useful principle is:

Inspection interviews evaluate understanding, not memorisation.

Why Inspectors Conduct Interviews

Interviews provide information that documents alone cannot.

Inspectors use interviews to:

Interviews often help inspectors determine whether processes operate as described (GVP Module III; GVP Module I).

What Inspectors Are Trying to Determine

Although questions vary, inspectors commonly seek answers to a small number of core questions.

Does the Individual Understand Their Role?

Are Responsibilities Clearly Defined?

Are Risks Visible?

Are Escalation Processes Effective?

Does Operational Reality Match Documentation?

Most interview questions ultimately support one or more of these objectives (Directive 2001/83/EC; Regulation (EC) No 726/2004; GVP Module I).

Who Gets Interviewed?

Interviewees commonly include:

The exact selection depends upon inspection scope (GVP Module III).

The QPPV Interview

The QPPV interview is often one of the most important inspection discussions.

Inspectors frequently explore:

The objective is generally to understand how the QPPV maintains oversight and demonstrates compliance with legal obligations (Regulation (EC) No 726/2004; Directive 2001/83/EC; GVP Module I).

Common QPPV Questions

Examples include:

Notice that these questions focus on oversight rather than operational details.

Vendor Oversight Questions

Vendor oversight remains a major inspection focus. Questions may include:

Inspectors often evaluate whether outsourced activities remain under effective control (GVP Module I; GVP Module II).

Audit and CAPA Questions

Inspectors frequently explore assurance activities. Examples include:

The quality of responses often reflects governance maturity (ICH Q9; ICH Q10).

PSMF Questions

Common discussion areas include:

Inspectors often compare interview responses against PSMF content. Consistency is important (GVP Module II).

Interview Preparation

Effective preparation focuses on understanding rather than rehearsing scripts.

Preparation activities may include:

The goal is confidence and clarity.

Understanding Your Responsibilities

One of the most common interview weaknesses occurs when individuals cannot clearly explain:

Every interviewee should understand:

Understanding Governance

Inspectors frequently explore governance arrangements. Examples include:

Interviewees should understand how decisions are made and how issues are escalated (GVP Module I; ICH Q10).

Understanding Current Risks

Interviewees should generally understand:

Inspectors often view awareness of risk as evidence of effective oversight (ICH Q9).

During the Interview

Several principles help improve interview quality.

These behaviours support effective communication.

When You Do Not Know the Answer

One of the most important interview skills is handling uncertainty appropriately.

A useful response may be:

I would like to verify that information before responding.

Inspectors generally prefer accurate information delivered later rather than incorrect information delivered immediately. Guessing creates unnecessary risk.

Common Interview Mistakes

Several weaknesses occur repeatedly.

These mistakes frequently create avoidable concerns.

Consistency Matters

Inspectors often compare:

Consistency across these sources increases confidence. Inconsistencies frequently trigger additional questions.

A useful principle is:

Consistency builds credibility.

Difficult Questions

Some questions may focus on:

Strong responses generally:

Inspectors are often interested in organisational learning rather than perfection.

Mock Interviews

Many organisations perform mock inspection interviews. Potential benefits include:

Mock interviews can be particularly valuable for QPPVs and senior pharmacovigilance personnel.

What Strong Interviewees Demonstrate

Strong interviewees typically demonstrate:

These characteristics often influence inspector confidence significantly.

What Inspectors Remember

Inspectors may not remember every answer. They often remember:

This reinforces an important point:

Interviews are assessments of control and oversight, not memory tests.

Key Takeaways

Inspection‑Ready Checklist

Below is a practical, inspector‑focused checklist organised by category. For each item include where it is located (electronic path / PSMF section / SOP number), the responsible owner, and the last update date. Many inspectors will ask to see the PSMF first; ensure cross‑referencing between PSMF sections and the documents below.

Preparation priority: High = must have available at inspection start; Medium = should be available on request; Low = available within agreed timeframe.

Inspection logistics checklist

Inspection conduct expectations

Governance and Practical Implementation Details

Clear governance underpins credible interview responses. Below are focused governance components, their inspection relevance and practical implementation actions.

  1. QPPV nomination and authority
  2. Regulatory context: The QPPV must be a resident in the EU and have the authority to fulfil legal obligations (Directive 2001/83/EC; Regulation (EC) No 726/2004).
  3. Implementation: Maintain a nomination package: signed appointment letter, JML (job, mobilities, limits), contract clause describing authority to request information and stop supply where needed.

  4. Inspection relevance: Inspectors will verify that the QPPV has clear authority and documented evidence of appointment and access to senior management.

  5. Delegation and deputies

  6. Governance: Delegation log with clear limits; deputies must be trained and formally delegated.
  7. Implementation: Keep an up‑to‑date delegation log, deputy CVs, and evidence of cross‑cover training.

  8. Inspection relevance: Demonstrates continuity—inspectors may ask who covers when the QPPV is unavailable.

  9. PSMF ownership and maintenance

  10. Regulatory context: PSMF must be maintained and reflect organisation and PV system (GVP Module II).
  11. Implementation: Assign a PSMF owner, schedule quarterly reviews for organisational changes, maintain version control and index.

  12. Inspection relevance: Inspectors use PSMF as a roadmap; discrepancies between PSMF and practice are queried.

  13. Escalation and management oversight

  14. Governance: Defined escalation criteria (timeliness, severity thresholds, business risks).
  15. Implementation: SOP for escalation, flowcharts, committee charters (safety risk committee), minutes of meetings.

  16. Inspection relevance: Inspectors probe how significant safety concerns reach the QPPV and senior management.

  17. Vendor oversight and subcontractor control

  18. Governance: Risk‑based vendor classification and oversight plan.
  19. Implementation: Vendor inventory in PSMF; risk assessment template; monitoring plan; evidence of KPIs and regular meetings; audit reports; CAPA tracking.

  20. Inspection relevance: Inspectors expect oversight proportional to risk—critical vendors should have recent audits and ongoing monitoring.

  21. Audit, CAPA and effectiveness checks

  22. Governance: Audit program integrated with risk register.
  23. Implementation: Audit schedule, findings log, CAPA register with owners, dates, and effectiveness verification evidence.

  24. Inspection relevance: Inspectors will review closed CAPAs for evidence of effective resolution and sustainability.

  25. Metrics, monitoring and management review

  26. Governance: Defined PV metrics and reporting frequency.
  27. Implementation: KPI dashboard, trend analyses, management review minutes documenting decisions and actions (ICH Q10).
  28. Inspection relevance: Inspectors use metrics to evaluate system performance and look for trend analysis and corrective action where indicated.

Inspection Relevance: What Will Trigger Follow‑Up?

For each governance element, inspectors typically expect documentary evidence and will follow up on:

When follow‑up occurs, record the request and provide a committed timeline. Failure to provide evidence within the agreed timeframe will be noted in inspection findings (GVP Module III).

Inspection‑Ready Example Responses for the QPPV — Sample Answers Mapped to Documentary Evidence and Regulatory Citations

Below are model QPPV answers to common inspection questions. Each answer is followed by suggested documentary evidence and the regulatory citations inspectors expect to see. These examples are intentionally concise and structured so they can be adapted to the specific organisation.

Note: tailor each response to actual facts. The mapping shows the types of documents inspectors will request.

Question 1 — "How is your pharmacovigilance system organised?"

Sample answer: "Our pharmacovigilance system is organised with the QPPV accountable for overall PV oversight, supported by regional PV leads, safety scientists for case processing, a vendor management function for contracted activities, and a PV quality unit responsible for audits and CAPAs. Day‑to‑day activities are performed by the safety database team, medical information and regulatory affairs. Oversight is maintained through weekly operational meetings, monthly KPI reviews and quarterly management review meetings."

Documentary evidence: - PSMF section: organisational structure and responsibilities (GVP Module II) - Organisational chart showing PV functions (PSMF annex) - Delegation log and job descriptions for QPPV, deputies and PV leads (GVP Module I) - SOP: PV governance and roles (SOP PV‑GOV‑001) - Minutes: weekly operational meeting, monthly KPI report, most recent management review minutes (ICH Q10) - QPPV nomination letter and CV (Directive 2001/83/EC; Regulation (EC) No 726/2004)

Inspection relevance: - Inspector will compare PSMF org chart to actual delegation log and meeting minutes. Discrepancies prompt deeper questions.

Question 2 — "What are the most significant risks to your pharmacovigilance system right now?"

Sample answer: "Our principal risks are (1) vendor dependency on the primary case processor, (2) timeliness of follow‑up information for serious cases, and (3) increased reporting volume from a new product launch. We manage these through vendor risk assessments, SLAs with explicit timelines and penalties, increased resourcing for safety team during launch and daily oversight of case timeliness metrics."

Documentary evidence: - Risk register entries for vendor dependency and launch‑related surge (ICH Q9) - Vendor risk assessment and PVA clauses (GVP Module I) - KPI dashboard and case timeliness metrics (safety database exports) - Temporary resourcing plan and training records - CAPA or escalation actions relating to previous similar issues

Regulatory citation: - Risk management expectations described in GVP Module I and ICH Q9. Inspection relevance: - Inspector will ask for the risk assessment and evidence that mitigation (e.g., additional staff, SLA enforcement) is in place and effective.

Question 3 — "How do you oversee outsourced pharmacovigilance activities?"

Sample answer: "We classify vendors by criticality and apply a risk‑based oversight plan. For critical vendors, we have initial qualification audits, quarterly performance reports, monthly governance calls and annual re‑audits. Contracts include clear PV obligations and data security clauses. We maintain a vendor dashboard that feeds into our management review."

Documentary evidence: - Vendor inventory and criticality classification in the PSMF (GVP Module II) - Contract/PVA with key vendors with explicit PV clauses (GVP Module I) - Audit reports: initial qualification audit and most recent audit (dates, findings) - Vendor performance reports and meeting minutes (vendor KPI dashboard) - CAPA tracker showing open/closed vendor CAPAs with effectiveness checks

Regulatory citation: - Expected vendor oversight per GVP Module I and II; data handling per Implementing Regulation (EU) No 520/2012.

Inspection relevance: - Inspectors will request contracts, audit reports and evidence that vendor CAPAs have been implemented and verified effective. Lack of these will be raised as a finding.

Question 4 — "How do you monitor compliance and know the system is working effectively?"

Sample answer: "We monitor through a set of KPIs focused on case intake, processing timeliness, quality checks, signal detection inputs and PSUR/PBRER timelines. Audit results and CAPA effectiveness checks are reviewed quarterly. We escalate issues through defined thresholds to the safety risk committee and capture decisions in management review."

Documentary evidence: - KPI dashboard with trend analysis (safety database extracts) (ICH Q10) - SOP for metrics and reporting (SOP PV‑METRICS) - Audit plan and recent audit reports (GVP Module I) - CAPA register with evidence of effectiveness checks - Safety risk committee charter and minutes; management review minutes

Regulatory citation: - Governance and quality systems as per GVP Module I and ICH Q10.

Inspection relevance: - Inspectors will expect trend data, evidence of follow‑up for out‑of‑tolerance metrics and completed effectiveness checks.

Question 5 — "How do significant issues reach your attention?"

Sample answer: "Significant issues are escalated via our escalation SOP: they are flagged in the KPI dashboard or through audit/CAPA findings, entered into the risk register if material, and referred to the safety risk committee for decision. If urgent, immediate notifications are sent to the QPPV and senior management."

Documentary evidence: - SOP: escalation and reporting (SOP PV‑ESCALATE) - Escalation log examples and emails to QPPV - Safety risk committee minutes for recent escalations - Risk register entries showing traceability

Regulatory citation: - Required governance and escalation practices per GVP Module I.

Inspection relevance: - Inspectors will ask for examples of recent escalations and trace them to committee minutes and actions.

Question 6 — "How is the PSMF maintained and how often is it reviewed?"

Sample answer: "The PSMF is maintained by the PSMF owner. The PSMF is formally reviewed at least annually and within 30 days of any significant organisational change (e.g., new vendor, change in QPPV, major M&A activity). Changes are controlled through our document control SOP and recorded in the version history."

Documentary evidence: - PSMF version history and revision log (PSMF cover page) - PSMF owner declaration (contact details) - SOP for document control and PSMF maintenance (SOP DOC‑CTRL) - Records of the latest PSMF review and any interim updates (PSMF change control records)

Regulatory citation: - PSMF requirements and maintenance guidance (GVP Module II).

Inspection relevance: - Inspectors will check whether the PSMF reflects current operations and recent organisational changes.

Question 7 — "What actions did you take following the last PV audit/inspection finding?"

Sample answer: "Following the audit, we implemented three CAPAs: updated the SOP for case triage, retrained staff on SAE identification, and restructured the vendor oversight cadence. CAPAs were assigned owners, closure dates, and effectiveness checks. Effectiveness was verified via subsequent mini‑audit and KPI improvements."

Documentary evidence: - Audit report with findings and severity classifications - CAPA register showing assigned owners, due dates, and completion evidence - Effectiveness check records (mini‑audit report, KPI snapshots pre/post) - Training records showing completed retraining

Regulatory citation: - Expectations for audit response and CAPA management (GVP Module I; ICH Q10).

Inspection relevance: - Inspectors will want to see traceability from finding to CAPA to evidence of effective resolution.

Practical Tips for Mapping Documents to Interview Answers

How to Maintain Inspection Readiness (Operational Steps)

  1. Assign owners: For each document in the checklist assign a named owner and deputy.
  2. Schedule reviews: Quarterly review cycles for high‑priority documents; annual formal PSMF review (GVP Module II).
  3. Run periodic mock interviews: Focus on governance questions and mapping answers to documents.
  4. Strengthen cross‑functional links: Ensure regulatory affairs, RA‑submissions, clinical, manufacturing and quality understand PV escalation triggers and where evidence is stored.
  5. Test access: Quarterly test of remote and on‑site access to PSMF, SOPs and KPI dashboards.
  6. Close loop on CAPAs: Ensure CAPAs include an effectiveness verification date and evidence; log this in the CAPA register.
  7. Maintain an inspection log: Record all inspection requests, documents provided, and timelines for follow‑up.

Regulatory expectation: organisations must be able to demonstrate system effectiveness and make the PSMF available to inspectors on request (GVP Module II; GVP Module III).

Summary of Inspection Relevance and Governance Responsibilities

References

  1. EMA Good Pharmacovigilance Practices (GVP) Module III – Pharmacovigilance Inspections.
  2. EMA Good Pharmacovigilance Practices (GVP) Module I – Pharmacovigilance Systems and Their Quality Systems.
  3. EMA Good Pharmacovigilance Practices (GVP) Module II – Pharmacovigilance System Master File.
  4. Regulation (EC) No 726/2004.
  5. Directive 2001/83/EC.
  6. Commission Implementing Regulation (EU) No 520/2012.
  7. ICH Q9 Quality Risk Management.
  8. ICH Q10 Pharmaceutical Quality System.
  9. PIC/S Guidance on Pharmacovigilance Inspections.

Related Articles

Inspection Hosting for QPPVs

A practical guide for QPPVs hosting pharmacovigilance inspections, including preparation, inspection management, interviews, document control and regulatory interactions.

Inspection Findings in Pharmacovigilance

A practical guide to inspection findings, regulatory significance, finding classification, CAPAs and inspection follow-up.

Inspection Readiness in Pharmacovigilance

A practical guide to inspection readiness, inspection preparation, governance maturity and sustainable compliance.

Last reviewed: 2026-06-11